ArticleHealth science reports2025
Suzetrigine - A Novel FDA-Approved Analgesic - Opportunities, Challenges and Future Perspectives: A Perspective Review.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A suzetrigine-based multimodal analgesic protocol in spine surgery: a single-center retrospective cohort study of opioid consumption, pain, and length of stay.North American Spine Society journal · 2026Article
- Article
- Selective NaV1.8 Inhibition for Pain Management: Current Evidence and Future Potential of Suzetrigine.Current pain and headache reports · 2026Review
- Review
- Suzetrigine - A Novel FDA-Approved Analgesic - Opportunities, Challenges and Future Perspectives: A Perspective Review.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Suzetrigine is the first class of non-opioid analgesics that selectively targets and blocks a key mediator in pain signal transmission, NaV1.8, which is expressed in the peripheral nociceptive neurons. Suzetrigine received approval from the U.S. Food and Drug Administration (FDA) on January 30, 2025. This review aims to explore Suzetrigine, a newly FDA-approved analgesic, by discussing its clinical opportunities, associated challenges, and future directions in pain management. Methods: We searched major databases (PubMed, Scopus, Web of Science, and ClinicalTrials.gov) and FDA sources for information on Suzetrigine and its role in pain management. The collected preclinical, clinical, and regulatory data were reviewed and analyzed to highlight their current evidence, challenges, and future potential. Result and Discussion: Suzetrigine has been approved to treat acute pain after a sufficient and acceptable clinical trial. In terms of its usage in treating chronic pain, its effectiveness in cases of pregnant or lactating women and children, as well as whether it can be used in combination therapy, are still under observation. The brand name of Suzetrigine is JOURNAVX. So far, enough evidence has been provided to approve this drug only to treat acute pain for a short period of time. A lot of people with short-term pain are concerned about getting addicted to opioid analgesics when they are used as postoperative pain relievers. The invention of Suzetrigine focused on combating these sorts of phenomena. Conclusion: Suzetrigine is considered an alternative option in the realm of acute pain management. Due to its selectivity, this medication does not interfere with other local anesthetics. Moreover, this selectivity also constrains this medication to act on other receptors, thus possessing the least amount of adverse effects. Although Suzetrigine created many opportunities for research in the field of pain management, but also opened a door for many uncertainties that cannot be ignored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.